戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ity and efficiency of the nanostructure as a drug delivery vehicle.
2 lls; thus, they are under consideration as a drug delivery vehicle.
3 ion in broad applications, particularly as a drug delivery vehicle.
4 he bottom graphene layer upward to mimic the drug delivery vehicle.
5 H as the trigger, making dendrimers a unique drug delivery vehicle.
6 stasis and serve as an implant-site targeted drug-delivery vehicle.
7          Nanoparticle carriers are effective drug delivery vehicles.
8 eir biocompatibility, EVs are widely used as drug delivery vehicles.
9 ers of disease, as therapeutic agents and as drug delivery vehicles.
10  understanding of polymeric nanoparticles as drug delivery vehicles.
11 used for tuning the mechanical properties of drug delivery vehicles.
12 ing phage are potential imaging tools and/or drug delivery vehicles.
13 es of nanowires and photonic systems, and as drug delivery vehicles.
14 heir potential utility as nanobioreactors or drug delivery vehicles.
15  implications in evaluating the stability of drug delivery vehicles.
16 s have been developed and used clinically as drug delivery vehicles.
17 a new mechanism for the design of controlled drug delivery vehicles.
18 ntercellular communication, and potential as drug delivery vehicles.
19 icles with high potential as next generation drug delivery vehicles.
20 ommunicators and have been proposed as ideal drug delivery vehicles.
21 yer of the cell membrane and are also useful drug delivery vehicles.
22  are increasingly being studied as potential drug delivery vehicles.
23 acted a lot of attention as potent versatile drug delivery vehicles.
24 nisms, for applications as protocells, or as drug-delivery vehicles.
25 CDPs) have drawn recent interest as drugs or drug-delivery vehicles.
26 photoacoustic imaging and as light-activated drug-delivery vehicles.
27 as the development of novel therapeutics and drug-delivery vehicles.
28 l barriers that are impermeable to synthetic drug-delivery vehicles.
29 plications: (1) metal-containing polymers as drug delivery vehicles; (2) metal-containing polymeric d
30  study mark the establishment of an amenable drug delivery vehicle and highlight the advantages of a
31                    Despite its wide use as a drug delivery vehicle and the recent approval of a clini
32 cent years as potential therapeutic targets, drug delivery vehicles and biomarkers of disease.
33 e then apply these MCP-based formulations as drug delivery vehicles and demonstrate greater colloidal
34        Nanoparticle-based materials, such as drug delivery vehicles and diagnostic probes, currently
35 r biomedical applications as optical labels, drug-delivery vehicles and contrast agents in vivo.
36 uses including as anti-cancer agents, ocular drug delivery vehicles, and protein trafficking modulato
37  potential to be used as anti-tumor therapy, drug delivery vehicles, and tools for imaging the TME.
38  drug discovery, continuous manufacturing of drug delivery vehicles, and ultra-precise dosing of high
39                           Nanomaterial-based drug delivery vehicles are able to deliver therapeutics
40                                              Drug delivery vehicles are often assessed for their abil
41 s, peptides, proteins, tissue scaffolds, and drug delivery vehicles, are conjugated to poly(ethylene
42 rticles have great potential as controllable drug delivery vehicles because of their size and modular
43 l structures with high potential as advanced drug delivery vehicles, bioreactors and artificial cells
44 bicide formulations can function not only as drug delivery vehicles, but also as physical barriers to
45 ults suggest that IF7 serves as an efficient drug delivery vehicle by targeting Anxa1 expressed on th
46                                    Nanoscale drug delivery vehicles can facilitate multimodal therapi
47                     The development of smart drug delivery vehicles capable of controlled release upo
48  Polymeric nanocarriers (PNCs) are versatile drug delivery vehicles capable of delivering a variety o
49                                    Design of drug delivery vehicles, cell and tissue matrices, and im
50         The therapeutic efficacy of systemic drug-delivery vehicles depends on their ability to evade
51 materials have recently emerged as promising drug delivery vehicles due to evidence of strong cellula
52 vesicles (EVs) have emerged as biocompatible drug delivery vehicles due to their native ability to de
53 9) have previously demonstrated promise as a drug delivery vehicle for chronic diseases due to their
54 been part-modified with a polyoxazoline as a drug delivery vehicle for improving the therapeutic inde
55 articles (LNPs) are the preeminent non-viral drug delivery vehicle for mRNA-based therapies.
56  serum albumin (HSA) as a solubilising agent/drug delivery vehicle for pulmonary administration of an
57   Lipid nanoparticles (LNPs) are a promising drug delivery vehicle for siRNAs.
58 roxyl PAMAM dendrimers could be an effective drug delivery vehicle for targeting fetal inflammation a
59 Here, we designed and tested a novel nanogel drug delivery vehicle for the immunosuppressant mycophen
60        Exosomes hold unrivaled benefits as a drug delivery vehicle for treating brain diseases due to
61                 Lipid nanoparticles serve as drug delivery vehicles for biopharmaceutical products.
62 argeted liposomes long garnering interest as drug delivery vehicles for cancer therapeutics, inconsis
63             Liposomes have been evaluated as drug delivery vehicles for decades, but their clinical s
64 -organized nanomicelles are highly efficient drug delivery vehicles for hydrophobic and partially hyd
65 y poly(amine-co-ester) (PACE) nanoparticles, drug delivery vehicles for nucleic acid and small molecu
66 articles (HNPs) have shown huge potential as drug delivery vehicles for pancreatic cancer.
67 vestigate whether these MEs could be used as drug delivery vehicles for prolonged release through in-
68 anoparticles (LNPs, the frontrunner class of drug delivery vehicles for translational mRNA therapy ut
69 itation of drugs and polymers, are promising drug delivery vehicles for treating diseases with improv
70 and summarize the current research on NPs as drug delivery vehicles for treating pregnancy-related di
71  of lipid bilayers have been investigated as drug-delivery vehicles for almost 20 years.
72 related apoptosis-inducing ligand (TRAIL) as drug-delivery vehicles for targeting and eradicating GBM
73 ions in developing cost-effective controlled drug delivery vehicles from renewable resources, with a
74       The magneto-plasmonic JVs were used as drug delivery vehicles, from which the release of a payl
75                     The use of exosomes as a drug delivery vehicle has gained considerable interest.
76  use of nanoporous silica-based materials as drug-delivery vehicles has recently proven successful, y
77                                    Nanoscale drug delivery vehicles have been harnessed extensively a
78                                         Many drug delivery vehicles have emerged, but liposomes are c
79    To address this issue, stents coated with drug-delivery vehicles have been developed to deliver an
80                                              Drug-delivery vehicles have great potential to improve t
81  exosomes limits their use as an anti-cancer drug delivery vehicle; however, when delivered intratumo
82                   Nanomaterials and targeted drug delivery vehicles improve the therapeutic index of
83 e findings could inform the design of future drug delivery vehicles in applications beyond intracellu
84 icancer drug doxorubicin (DOX) are efficient drug delivery vehicles in cancer therapy using pH-respon
85 hat have attracted considerable attention as drug delivery vehicles in the past few years.
86 hanisms and recent developments in different drug delivery vehicles, including the quantum dots, nano
87         A light-activated hypoxia-responsive drug-delivery vehicle is described by Q.-D. Shen, Z. Gu,
88 ry, as well as the cellular response to mRNA drug delivery vehicles, is conserved across species in v
89  sought to design a family of HP-beta-CD pro-drug delivery vehicles, known as polyrotaxanes (PR), cap
90 d to enhance product formulations, including drug delivery vehicles, medical imaging contrast agents,
91 hallenging due to the harsh environments any drug- delivery vehicle must experience before it release
92                    This study indicates that drug delivery vehicles, nanoemulsions specifically, enha
93 technologies have repurposed erythrocytes as drug-delivery vehicles, opening new avenues for therapeu
94 e and rigidity, have been exploited as novel drug delivery vehicles over the past decade.
95 Exosomes are also a promising class of novel drug delivery vehicles owing to their ability to shield
96 are a versatile class of clinically approved drug delivery vehicles, particularly for nucleic acid ca
97 nstrated by the discovery of a candidate CNS drug delivery vehicle ready for further optimization and
98           Harnessing exosomes as therapeutic drug delivery vehicles requires a better understanding o
99             Fabrication of stimuli-triggered drug delivery vehicle s is an important milestone in tre
100  can be achieved with appropriately designed drug delivery vehicles such as nanoparticles, adult stem
101                                              Drug delivery vehicles such as polymeric nanoparticles (
102               Inflammatory components of the drug delivery vehicle, T cell responses, T and B cell ep
103 rtments, and designed capsules, as vaccines, drug delivery vehicles, targeted imaging agents, nanorea
104 strategy is limited by the lack of efficient drug delivery vehicles targeting this cell compartment.
105 ent of pH-responsive nanoparticle-based dual drug delivery vehicles that are potentially capable of b
106 barriers requires the use of multifunctional drug delivery vehicles that can overcome a wide range of
107                                   Therefore, drug delivery vehicles that deliver effective anti-infla
108 yer-by-layer nanoparticles (NPs) are modular drug delivery vehicles that incorporate multiple functio
109 the potential use of these macromolecules as drug delivery vehicles, the poorly water-soluble antican
110 ive distribution of solutes such as drugs or drug delivery vehicles through the vitreous humor.
111 nstrate that ssDNA nanotubes are a promising drug delivery vehicle to glioblastoma.
112 on of a plethora of functional constructs as drug delivery vehicles to address many dire medical need
113 otechnologies ranging from imaging probes to drug delivery vehicles to regenerative medicine, inexpen
114 fect an array of applications from design of drug delivery vehicles to tissue engineering systems.
115 imprints also have applications as selective drug delivery vehicles to tumours with the potential to
116                  The BOSP also was used as a drug-delivery vehicle to treat corneal ulcers successful
117 ate targeting mechanisms, and can be used as drug-delivery vehicles to increase the efficiency with w
118  for a variety of applications, ranging from drug-delivery vehicles to molecular sensors.
119 herwise functionalized polymeric particulate drug delivery vehicles, typical biocompatible particles
120 ial of a cyclodextrin-based nanocarrier as a drug delivery vehicle, using cell monolayers in vitro in
121 to the design of more effective nucleic acid drug delivery vehicles which take advantage of crotamine
122 ials also makes them excellent candidates as drug delivery vehicles, which is the focus of this revie
123 ied the synthesis of antibody-functionalized drug delivery vehicles, which were benchmarked against a
124 the promise of MTV MOF design for optimizing drug delivery vehicles with relevant payloads and patien
125 iction of mucosal passage, and the design of drug delivery vehicles with tunable transport properties
126 mi has enabled the development of responsive drug-delivery vehicles with precision features that were

 
Page Top